We are live on ! Find out more

869 hedge funds and large institutions have $16.3B invested in Biogen in 2025 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 342 increasing their positions, 267 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

28% more repeat investments, than reductions

Existing positions increased: 342 | Existing positions reduced: 267

14% more call options, than puts

Call options by funds: $381M | Put options by funds: $333M

2% more capital inflows, than outflows

Capital inflows: $1.49B | Capital outflows: $1.47B

0.04% less ownership

Funds ownership: 88.84% → 88.8% (-0.04%)

8% less first-time investments, than exits

New positions opened: 94 | Existing positions closed: 102

2% less funds holding

Funds holding: 887 → 869 (-18)

Holders
869
Holders Change
-18
Holders Change %
-2.03%
% of All Funds
11.39%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.07%
New
94
Increased
342
Reduced
267
Closed
102
Calls
$381M
Puts
$333M
Net Calls
+$47.6M
Net Calls Change
+$323M

BIIB Hedge Fund Activity: Q2 2025 in Review

869 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2025, worth a combined $16.3B — down 8.1% from $17.8B a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of BIIB and 94 opened new positions — a net loss of 8 holders — while 267 trimmed existing stakes and 342 added.

The largest buyer was Point72 Asset Management, adding an estimated $427M. The largest seller was BlackRock, cutting an estimated $206M.

  • 869 institutional investors held Biogen (BIIB) as of Q2 2025, down from 887 in Q1 2025.
  • Funds reported $16.3B of Biogen stock for Q2 2025, down 8.1% quarter-over-quarter.
  • 94 funds opened new Biogen positions in Q2 2025 and 102 closed out, a net change of -8 holders.
  • The largest Biogen buyer in Q2 2025 was Point72 Asset Management, an estimated $427M added.
  • The largest Biogen seller in Q2 2025 was BlackRock, an estimated $206M sold.

Based on aggregated 13F filings for Q2 2025.